USP <85> Bacterial Endotoxin (LAL) Testing: A Practical Guide for Compounding Teams

Endotoxin control is invisible until it is not

Bacterial endotoxins—lipopolysaccharides from Gram-negative bacteria—can trigger serious febrile and inflammatory responses. For sterile preparations, USP <85> Bacterial Endotoxins Test (BET) is a cornerstone control, typically performed with Limulus Amebocyte Lysate (LAL) based methods (and related recombinant approaches where scientifically justified and accepted in your quality system).

Compounding pharmacies and 503B facilities often outsource <85> because the assay demands technique, interference control, and rigorous documentation. This guide focuses on practical decision-making: when to test, what to tell a contract lab, and how to judge competence.

Where endotoxin testing fits in the release puzzle

Endotoxin testing complements—not replaces—sterility testing, container-closure integrity strategy, process controls, and water system quality. Typical touchpoints:

• Finished sterile preparations (when required by monograph, SOP, or risk assessment)
• Pharmaceutical water systems (as part of water quality monitoring)
• Certain raw materials and components based on risk
• Investigations after water excursions, bioburden events, or patient complaints with febrile signals

Your SOP should define which products and which lots require <85>, acceptance criteria, and what happens on failure.

Method families you will hear about

Without turning this into a method-validation textbook, know the common commercial approaches:

• Gel-clot — traditional endpoint; still widely understood by auditors
• Turbidimetric kinetic methods
• Chromogenic kinetic methods
• Recombinant Cascade / rFC-type approaches — increasingly discussed; confirm acceptance in your regulatory/quality context before switching

The “best” method is the one that is suitable for your matrix, validated/suitable in lab hands, and reportable with clear assay controls.

Interference is the plot twist

Product matrices can inhibit or enhance the LAL reaction. That is why laboratories perform inhibition/enhancement (suitability) work. If a lab quotes endotoxin testing but shrugs at interference screening for a new product, treat that as a risk signal.

Tell the lab up front:

• Formulation highlights (proteins, chelators, organic solvents, extreme pH, liposomes, etc.)
• Preservatives
• Expected endotoxin limit and units (EU/mg, EU/mL, etc.)
• Dilution constraints driven by dose and limit calculations

A strong CTL will propose a dilution/treatment strategy rather than hoping the first run “just works.”

Sampling and handling mistakes that create false stories

Endotoxin is sticky and opportunistic. Contaminated glassware, poor depyrogenation practices, and sloppy sampling can raise results that do not reflect the batch.

Coordinate with the lab on:

• Validated depyrogenated sample containers (or lab-provided containers)
• Fill volume needed for the assay + retests
• Storage conditions and hold times
• Whether to send product in original containers vs aseptically transferred aliquots

Document chain of custody. If an OOS occurs, you will need it.

How to evaluate a contract lab for USP <85>

Technical

• Documented LAL method competency and suitable equipment maintenance
• Clear suitability workflow for new products
• Trained analysts and second-person review culture
• Ability to support investigations with raw data packages

Quality system

• ISO/IEC 17025 scope covering bacterial endotoxins / LAL as applicable
• Change control for lysate vendor or method revisions
• Transparent out-of-specification procedures

Operational

• Realistic TAT that includes suitability for first-time products
• Weekend accessioning expectations if you ship late week
• Rush pathways that do not skip controls

Search LabCompare Rx for labs offering USP <85> / endotoxin capabilities and ask for a sample report plus suitability outline.

Reading results and limits without self-owning your investigation

Before you ship:

• Confirm the endotoxin limit calculation basis used by your SOP
• Confirm units and product-specific maximum valid dilution concepts the lab will apply
• Agree how inconclusive / invalid assays are billed and timed

On failure:

• Distinguish lab invalid assays from true product failures
• Preserve retain samples
• Involve the lab early in hypothesis generation (water, components, process hold points)

Endotoxin vs sterility: do not conflate them

Pharmacies sometimes ask, “If sterility passed, why test endotoxin?” Because they measure different risks. A preparation can be sterile and still carry endotoxin from dead Gram-negative organisms or contaminated inputs. Keep the tests conceptually separate in training so purchasing does not “optimize away” one based on the other.

Quote requests that get useful answers

Send:

1. Product description and limit
2. Method preference if any (or ask for recommendation)
3. Whether this is a first-time suitability or routine lot release
4. Needed documentation (CoA only vs full packet)
5. Standard vs rush timing
6. Approximate monthly volume (helps capacity planning)

Then compare labs on suitability approach and investigation communication—not only per-test price.

Water systems and endotoxin: do not forget the upstream story

Many endotoxin problems originate in water or components rather than the compounding step that “gets blamed.” When you outsource finished-product <85>, also make sure your water monitoring strategy (and any outsourced water testing) is coherent. A CTL that understands pharmaceutical water contexts can help interpret patterns across sample types—if you share enough process context under CDA.

Building internal competence while outsourcing

Outsourcing <85> does not mean your team should be illiterate about the assay. Train buyers and QA on:

• Why limits exist
• What inhibition/enhancement means
• How to spot an invalid run vs a failing lot
• What retain strategy you need

That literacy makes vendor conversations sharper and investigations faster.

Bottom line

USP <85> protects patients from a risk you cannot see in a clear vial. The right contract lab treats interference, container control, and OOS communication as seriously as the assay itself. Qualify for competence and scope first, then negotiate speed and price among labs that already cleared that bar.

LabCompare Rx helps you shortlist endotoxin-capable CTLs and request structured quotes without inventing market prices.